Olink Holding AB (publ)

F:6XA

Olink Holding AB (publ), a Swedish biotechnology company, has carved a distinct niche within the life sciences landscape. Founded in 2016, Olink emerged from the innovative vision to enhance and accelerate the understanding of human biology. It achieves this through its proprietary Proximity Extension Assay (PEA) technology, which is designed to detect and quantify proteins with high precision. The company's technology serves the research community by providing valuable insights into the protein dynamics that underpin both rare and common diseases. By enabling scientists to delve deeper into protein biomarker discovery, Olink not only contributes to scientific understanding but also supports the development of personalized medicine and drug discovery. The ability to process a large number of samples with significant sensitivity and specificity makes Olink’s solutions indispensable for complex biological research.

Olink's business model revolves around providing comprehensive protein analysis services. This model includes a combination of selling reagent kits and offering in-house analytical services through Olink's labs. In this way, the company caters to a broad spectrum of researchers, whether they prefer to conduct experiments internally or outsource them. The revenue streams are bolstered by long-term partnerships with pharmaceutical companies, academic institutions, and clinical researchers who seek robust and scalable protein quantification solutions. These collaborations often extend beyond mere transactions, evolving into joint projects that harness Olink's technologies to tackle pressing challenges in proteomics. Thus, Olink not only monetizes its pioneering assays but also fosters a sustainable ecosystem of innovation and discovery within the scientific community.